APA (7th ed.) Citation

Klempner, S. J., Fabrizio, D., Bane, S., Reinhart, M., Peoples, T., Ali, S. M., . . . Reddy, P. (2020). Tumor Mutational Burden as a Predictive Biomarker for Response to Immune Checkpoint Inhibitors: A Review of Current Evidence. The oncologist (Dayton, Ohio), 25(1), e147-e159. https://doi.org/10.1634/theoncologist.2019-0244

Chicago Style (17th ed.) Citation

Klempner, Samuel J., et al. "Tumor Mutational Burden as a Predictive Biomarker for Response to Immune Checkpoint Inhibitors: A Review of Current Evidence." The Oncologist (Dayton, Ohio) 25, no. 1 (2020): e147-e159. https://doi.org/10.1634/theoncologist.2019-0244.

MLA (9th ed.) Citation

Klempner, Samuel J., et al. "Tumor Mutational Burden as a Predictive Biomarker for Response to Immune Checkpoint Inhibitors: A Review of Current Evidence." The Oncologist (Dayton, Ohio), vol. 25, no. 1, 2020, pp. e147-e159, https://doi.org/10.1634/theoncologist.2019-0244.